MiraDx Reaps $1M Investment From Connecticut Innovations | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MircoRNA test developer MiraDx has received a $1 million investment through the Eli Whitney Fund of Connecticut Innovations, a technology-focused economic development group, CI said today.

For the firm, which is based in New Haven, Conn., the $1 million investment is part of its Series A round of financing that will add up to a total of $4 million, CI said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.